Nuvalent (NASDAQ:NUVL) Sees Strong Trading Volume – Time to Buy?

Nuvalent, Inc. (NASDAQ:NUVL) saw an uptick in trading volume on Thursday . Approximately 1,265,389 shares traded hands during mid-day trading, a decline of 2% from the previous session’s volume of 1,285,246 shares.The stock last traded at $123.4750 and had previously closed at $123.36.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on NUVL. Piper Sandler lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 price objective on the stock. in a report on Tuesday, June 9th. Wells Fargo & Company restated an “equal weight” rating and issued a $124.00 target price (up from $116.00) on shares of Nuvalent in a research note on Tuesday, June 9th. Raymond James Financial cut Nuvalent from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 9th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Nuvalent in a research note on Wednesday, June 10th. Finally, TD Cowen lowered Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 price objective on the stock. in a report on Tuesday, June 9th. Five research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $131.15.

Nuvalent Stock Performance

The firm has a 50-day simple moving average of $106.11 and a two-hundred day simple moving average of $103.93. The company has a market capitalization of $9.75 billion, a price-to-earnings ratio of -20.37 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter last year, the business earned ($1.18) earnings per share. Equities research analysts anticipate that Nuvalent, Inc. will post -5.74 EPS for the current year.

Insider Buying and Selling

In other Nuvalent news, insider Deborah Ann Miller sold 5,500 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the transaction, the insider directly owned 59,634 shares of the company’s stock, valued at approximately $6,430,930.56. The trade was a 8.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Alexandra Balcom sold 11,430 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $105.21, for a total value of $1,202,550.30. Following the completion of the sale, the chief financial officer owned 85,533 shares in the company, valued at approximately $8,998,926.93. This represents a 11.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 126,953 shares of company stock valued at $12,612,264 in the last ninety days. Insiders own 5.02% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. purchased a new stake in shares of Nuvalent during the 3rd quarter worth about $107,794,000. Wellington Management Group LLP increased its stake in shares of Nuvalent by 46.0% in the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after purchasing an additional 724,491 shares in the last quarter. Vanguard Group Inc. raised its holdings in Nuvalent by 13.9% in the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock worth $527,521,000 after purchasing an additional 639,264 shares during the period. Norges Bank acquired a new position in Nuvalent in the 4th quarter worth about $57,763,000. Finally, JPMorgan Chase & Co. boosted its position in Nuvalent by 32.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock worth $221,826,000 after purchasing an additional 545,542 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.